Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Mini-Reviews in Medicinal Chemistry

Volume 9 Issue 6
ISSN: 1389-5575
eISSN: 1875-5607


   All Titles

  Farnesyltransferase Inhibitor as Anticancer Agent
  pp.638-652 (15) Authors: Anuj G. Agrawal, Rakesh R. Somani

Ras protein plays pivotal roles in control of normal and transformed cell growth. These ras genes are mutated in 30% of human cancer. For functioning of Ras protein its prenylation (farnesylation) is required. Therefore targeting Ras farnesylation is valuable approach for cancer treatment. Farnesyltransferase inhibitor (FTI) has been developed as anticancer drug and is currently evaluated in clinical trials. Different types of FTI have been identified that inhibit Ras farnesylation. FTI in combination with some cytotoxic antineoplastic drugs, exhibit additive effects.

  Keywords: Farnesyltransferase, ras protein, farnesyltransferase inhibitor
  Affiliation: Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Sec-8, CBD, Navi Mumbai-400 614, India.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers